3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
133
Squamous Cell Carcinoma of Head and Neck
76
Lung Neoplasms
49
Head and Neck Neoplasms
45
Urinary Bladder Neoplasms
43
Parkinson Disease 4, Autosomal Dominant Lewy Body
33
Oropharyngeal Neoplasms
32
Nasopharyngeal Carcinoma
32
Biliary Tract Neoplasms
31
Uterine Cervical Neoplasms
30
Cholangiocarcinoma
28
Esophageal Squamous Cell Carcinoma
26
Carcinoma
24
Neoplasms
23
Ovarian Neoplasms
22
Neoplasm Metastasis
22
Small Cell Lung Carcinoma
21
Carcinoma, Squamous Cell
20
Stomach Neoplasms
18
Colorectal Neoplasms
18
Carcinoma, Transitional Cell
17
Pancreatic Neoplasms
16
Esophageal Neoplasms
16
Mesothelioma, Malignant
15
Gallbladder Neoplasms
15
Mouth Neoplasms
14
Laryngeal Neoplasms
13
Hypopharyngeal Neoplasms
12
Endometrial Neoplasms
11
Triple Negative Breast Neoplasms
10
Interventions
pembrolizumab
2
darolutamide
2
relatlimab
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Surveys and Questionnaires
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Nivolumab
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
CP protocol
1
Blood Specimen Collection
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Male Urogenital Diseases
×
Cisplatin
×
1 year
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled